Advertisement
Research Article| Volume 21, ISSUE 12, P1114-1122, October 1986

Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Chronic administration of the neuroleptic haloperidol, the calcium channel antagonist nitrendipine, and the calcium channel antagonist neuroleptic pimozide produce differential effects on rat striatal 3H-spiperone binding. Following 7 days of 10 mg/kg i.p. administration, haloperidol significantly increases (p< 0.01) dopamine D2 receptor binding to 123% ± 6% of control values, whereas pimozide treatment significantly reduces (p < 0.001) striatal 3H-spiperone binding to 46% ± 6% of control values. Chronic administration of the calcium channel antagonist nitrendipine does not alter 3H -spiperone binding relative to control values. Saturation analysis reveals an increase in Bmaxfollowing chronic haloperidol and a decrease in Bmaxfollowing chronic pimozide treatment. No alterations in muscarinic cholinergic sites, dopamine uptake sites, or calcium channel antagonist sites result following chronic drug administration. These results are the first demonstration of a decrease in dopamine D2 binding sites after chronic neuroleptic treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Burt DR
        • Creese I
        • Snyder SH
        Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain.
        Science. 1977; 196: 326-328
        • Christensen AV
        • Fjalland B
        • Moller Nielsen I
        On the supersensitivity of dopamine receptors, induced by neuroleptics.
        Psychopharmacology (Berl). 1976; 48: 1-6
        • Claveria LE
        • Teychenne PF
        • Calne DB
        • Haskayne L
        • Petrie A
        • Pallis CA
        • Lodge-Patch IC
        Tardive dyskinesia treated with pimozide.
        J Neurol Sci. 1975; 24: 393-401
        • Costall B
        • Naylor RJ
        • Owen RT
        Behavioural correlates of modified dopaminergic/anticholinergic responses following chronic treatment with neuroleptic agents of differing activity spectra.
        Eur J Pharmacol. 1978; 48: 29-36
        • Dewey KJ
        • Fibiger HC
        The effects of dose and duration of chronic pimozide administration on dopamine receptor supersensitivity.
        Naunyn Schmiedeberg Arch Pharmacol. 1983; 322: 261-270
        • Ettenberg A
        • Milner PM
        Effects of dopamine supersensitivity on lateral hypothalamic selfstimulation in rats.
        Pharmacol Biochem Behav. 1977; 7: 509-514
        • Fibiger HC
        • Lloyd KG
        Neurobiological substrates of tardive dyskinesia: The GABA hypothesis.
        Trends Neurosci. 1984; 7: 462-464
        • Fog R
        • Pakkenberg H
        Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes.
        Acta Neurol Scand. 1970; 46: 249-251
        • Frangos H
        • Zissis NP
        • Leontopoulos I
        • Diamantas N
        • Tsitouridis S
        • Gavriil I
        • Tsolisk
        Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics.
        Acta Psychiatr Scand. 1978; 57: 436-446
        • Goetz CG
        • Weiner WJ
        • Nausieda PA
        • Klawans HL
        Tardive dyskinesia: Pharmacology and clinical implications.
        Clin Neuropharmacol. 1982; 5: 3-22
        • Gould RJ
        • Murphy KMM
        • Reynolds IJ
        • Snyder SH
        Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists.
        in: Proc Natl Acad Sci USA. 80. 1983: 5122-5125
        • Haas S
        • Beckmann H
        Pimozide versus haloperidol in acute schizophrenia. A double blind controlled study.
        Pharmacopsychiatria. 1982; 15: 70-74
        • Hitri A
        • Weiner WJ
        • Borison RL
        • Diamond BI
        • Nausieda PA
        • Klawans HL
        Dopamine binding following prolonged haloperidol pretreatment.
        Ann Neurol. 1978; 3: 134-140
        • Hyttel J
        Neurochemical parameters in the hyperresponsive phase after a single dose of neuroleptics to mice.
        J Neurochem. 1979; 33: 641-646
        • Jackson DM
        • Anden NE
        • Engel J
        • Liljequist S
        The effect of long-term penfluridol treatment on the sensitivity of the dopamine receptors in the nucleus accumbens and in the corpus striatum.
        Psychopharmacology (Berl). 1975; 45: 151-155
        • Javitch JA
        • Blaustein RO
        • Snyder SH
        [3H]Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites.
        Mol Pharmacol. 1984; 26: 35-44
        • Kobayashi RM
        • Fields JZ
        • Hruska RE
        • Beaumont K
        • Yamamura HI
        Brain neurotransmitter receptors and chronic antipsychotic drug treatment: A model for tardive dyskinesia.
        in: Hanin I Usdin E Animal Models in Psychiatry and Neurology. Pergamon Press, New York1977: 405-409
        • Lapierre YD
        A controlled study of penfluridol in the treatment of chronic schizophrenia.
        Am J Psychiatry. 1978; 135: 956-959
        • Marshall AM
        • Mishra RK
        Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: Effect of neuroleptic drugs.
        Adv Biochem Psychopharmacol. 1980; 24: 153-157
        • Martres MP
        • Costentin J
        • Baudry M
        • Marcais H
        • Protais P
        • Schwanz JC
        Long-term changes in the sensitivity of pre- and postsynaptic dopamine receptors in mouse striatum evidenced by behavioural and biochemical studies.
        Brain Res. 1977; 136: 319-337
        • Muller P
        • Seeman P
        Dopaminergic supersensitivity after neuroleptics: Time-course and specificity.
        Psychopharmacology (Berl). 1978; 60: 1-11
        • Murphy KMM
        • Gould RJ
        • Largent BL
        • Snyder SH
        A unitary mechanism of calcium antagonist drug action.
        in: Proc Natl Acad Sci USA. 80. 1983: 860-864
        • Peroutka SJ
        • Snyder SH
        Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histamine receptors to clinical potency.
        Am J Psychiatry. 1980; 127: 1518-1522
        • Pinder RM
        • Brogden RN
        • Sawyer PR
        • Speight TM
        • Spencer R
        • Avery GS
        Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry.
        Drugs. 1976; 12: 1-40
        • Rupniak NMJ
        • Kilpatrick G
        • Hall MD
        • Jenner P
        • Marsden CD
        Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
        Psychopharmacology (Berl). 1984; 84: 512-519
        • Seeman P
        Brain dopamine receptors.
        Pharmacol Rev. 1981; 32: 230-313
        • Shopsin B
        • Klein H
        • Gerbino L
        • Selzer G
        Penfluridol: An open phase III study in acute newly admitted hospitalized schizophrenic patients.
        Psychopharmacology (Berl). 1977; 55: 157-164
        • Silverstone T
        • Cookson J
        • Ball R
        • Chin CN
        • Jacobs D
        • Lader S
        • Gould S
        The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated wth pimozide or haloperidol.
        J Psychiatr Res. 1984; 18: 255-268
        • Tarsy D
        • Baidessarini RJ
        Tardive dyskinesia.
        Annu Rev Med. 1984; 35: 605-623
        • Thronburg JE
        • Moore K.E
        Supersensitivity to dopaminergic agonists following withdrawal of a chronic diet containing haloperidol or pimozide.
        Pharmacologist. 1974; 16: 307
        • Waddington JL
        • Galvin R
        Tardive dyskinesia: A critical re-evaluation of the causal role of neuroleptics and of the dopamine receptor Supersensitivity hypothesis.
        in: Callaghan N Recent Research in Neurology. Pitman, London1984: 34-48